Vol. 6 No. 7 (2026): July
Reimbursement Reviews

Lurbinectedin (Zepzelca)

decorative image of the issue cover

Published July 9, 2026

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses lurbinectedin (Zepzelca), 3.2 mg/m2, IV infusion over 1 hour.
  • Indication: Treatment of adult patients with Stage III or metastatic small cell lung cancer (SCLC) who have progressed on or after platinum-containing therapy.